Buparlisib
Tier C — Watch / tradeBuparlisib
Targets：PI3Kβ, PI3Kα, PI3Kγ, PI3Kδ
Indications (approved)：Head and neck squamous cell carcinoma, Solid tumour, 鼻咽肿瘤, 喉肿瘤, 口咽肿瘤, Squamous cell carcinoma, 下咽肿瘤, Breast cancer
Regional status
Synthetic routes & intermediates3 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| BUPA-001 | 157415-17-3 | morpholine-4-carboximidamide hydrobromide |
| BUPA-002 | 105-53-3Available | diethyl malonate |
| BUPA-003 | 24193-00-8 | 2-morpholinopyrimidine-4,6-diol |
| BUPA-004 | 10397-13-4 | 4-(4,6-dichloropyrimidin-2-yl)morpholine |
| BUPA-005 | 10244-24-3 | 4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine |
| BUPA-006 | 944401-57-4 | 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyridin-2-amine |
| BUPA-007 | 106447-97-6 | 4-(trifluoromethyl)pyridin-2-amine |
| BUPA-008 | 944401-56-3 | 5-bromo-4-(trifluoromethyl)pyridin-2-amine |
| BUPA-009 | 73183-34-3Available | 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) |
| Code | CAS No. | Intermediate |
|---|---|---|
| BUPA-005 | 10244-24-3 | 4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine |
| BUPA-008 | 944401-56-3 | 5-bromo-4-(trifluoromethyl)pyridin-2-amine |
| BUPA-009 | 73183-34-3Available | 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) |
| BUPA-010 | 1370351-45-3 | 4,4'-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine-2,4-diyl)dimorpholine |
| Code | CAS No. | Intermediate |
|---|---|---|
| BUPA-005 | 10244-24-3 | 4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine |
| BUPA-008 | 944401-56-3 | 5-bromo-4-(trifluoromethyl)pyridin-2-amine |
| BUPA-011 | 1607826-43-6 | magnesium (5-bromo-4-(trifluoromethyl)pyridin-2-yl)nitride dichloride |
Frequently asked questions
What are the approved indications of Buparlisib?
Approved indications include: Head and neck squamous cell carcinoma, Solid tumour, 鼻咽肿瘤, 喉肿瘤, 口咽肿瘤, Squamous cell carcinoma, 下咽肿瘤, Breast cancer.
When does the Buparlisib patent expire?
No public expiry year is available for Buparlisib yet; this page updates once verified.
How many synthesis routes are recorded for Buparlisib?
3 synthesis routes are recorded; the shortest is 2 steps with 75 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Buparlisib intermediates?
2 intermediate CAS of Buparlisib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Buparlisib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-18